Advanced Enzyme Technologies Limited researches and develops, manufactures, and markets enzymes and probiotics in India, the United States, Asia, Europe, and internationally. More Details
No risks detected for ADVENZYMES from our risk checks.
Flawless balance sheet with proven track record.
Share Price & News
How has Advanced Enzyme Technologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ADVENZYMES is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: ADVENZYMES's weekly volatility (6%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: ADVENZYMES exceeded the Indian Chemicals industry which returned 82.5% over the past year.
Return vs Market: ADVENZYMES exceeded the Indian Market which returned 66.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Advanced Enzyme Technologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall StWith EPS Growth And More, Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Interesting
2 weeks ago | Simply Wall StDo Institutions Own Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares?
1 month ago | Simply Wall StReturns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Paint A Concerning Picture
Is Advanced Enzyme Technologies undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: ADVENZYMES (₹456.55) is trading above our estimate of fair value (₹257.2)
Significantly Below Fair Value: ADVENZYMES is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ADVENZYMES is poor value based on its PE Ratio (35x) compared to the Indian Chemicals industry average (19.3x).
PE vs Market: ADVENZYMES is poor value based on its PE Ratio (35x) compared to the Indian market (19.7x).
Price to Earnings Growth Ratio
PEG Ratio: ADVENZYMES is poor value based on its PEG Ratio (2x)
Price to Book Ratio
PB vs Industry: ADVENZYMES is overvalued based on its PB Ratio (5.4x) compared to the IN Chemicals industry average (1.8x).
How is Advanced Enzyme Technologies forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ADVENZYMES's forecast earnings growth (17.6% per year) is above the savings rate (6.8%).
Earnings vs Market: ADVENZYMES's earnings (17.6% per year) are forecast to grow slower than the Indian market (22.3% per year).
High Growth Earnings: ADVENZYMES's earnings are forecast to grow, but not significantly.
Revenue vs Market: ADVENZYMES's revenue (12.6% per year) is forecast to grow slower than the Indian market (13.1% per year).
High Growth Revenue: ADVENZYMES's revenue (12.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ADVENZYMES's Return on Equity is forecast to be low in 3 years time (15.9%).
How has Advanced Enzyme Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ADVENZYMES has high quality earnings.
Growing Profit Margin: ADVENZYMES's current net profit margins (30.3%) are higher than last year (29.1%).
Past Earnings Growth Analysis
Earnings Trend: ADVENZYMES's earnings have grown by 12.5% per year over the past 5 years.
Accelerating Growth: ADVENZYMES's earnings growth over the past year (12.1%) is below its 5-year average (12.5% per year).
Earnings vs Industry: ADVENZYMES earnings growth over the past year (12.1%) exceeded the Chemicals industry 9.7%.
Return on Equity
High ROE: ADVENZYMES's Return on Equity (15.5%) is considered low.
How is Advanced Enzyme Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: ADVENZYMES's short term assets (₹4.8B) exceed its short term liabilities (₹549.0M).
Long Term Liabilities: ADVENZYMES's short term assets (₹4.8B) exceed its long term liabilities (₹398.0M).
Debt to Equity History and Analysis
Debt Level: ADVENZYMES is debt free.
Reducing Debt: ADVENZYMES has no debt compared to 5 years ago when its debt to equity ratio was 42.3%.
Debt Coverage: ADVENZYMES has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ADVENZYMES has no debt, therefore coverage of interest payments is not a concern.
What is Advanced Enzyme Technologies's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ADVENZYMES's dividend (0.13%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.41%).
High Dividend: ADVENZYMES's dividend (0.13%) is low compared to the top 25% of dividend payers in the Indian market (1.71%).
Stability and Growth of Payments
Stable Dividend: ADVENZYMES is not paying a notable dividend for the Indian market, therefore no need to check if payments are stable.
Growing Dividend: ADVENZYMES is not paying a notable dividend for the Indian market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: ADVENZYMES is not paying a notable dividend for the Indian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ADVENZYMES's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Advanced Enzyme Technologies has no CEO, or we have no data on them.
Experienced Management: ADVENZYMES's management team is seasoned and experienced (5.7 years average tenure).
Experienced Board: ADVENZYMES's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Advanced Enzyme Technologies Limited's company bio, employee growth, exchange listings and data sources
- Name: Advanced Enzyme Technologies Limited
- Ticker: ADVENZYMES
- Exchange: NSEI
- Founded: 1957
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: ₹51.004b
- Shares outstanding: 111.73m
- Website: https://www.advancedenzymes.com
Number of Employees
- Advanced Enzyme Technologies Limited
- Sun Magnetica
- 5th Floor, A wing
Advanced Enzyme Technologies Limited researches and develops, manufactures, and markets enzymes and probiotics in India, the United States, Asia, Europe, and internationally. The company offers enzymes for...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/16 12:02|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.